Sweden Läkemedelsverket — Scandinavian GLP-1 prescribing update

That's pretty accurate and yes, the irony of the Danish situation isn't lost on us. The Danish government has been cautious about the budget impact of covering GLP-1s for obesity given the large eligible population. There are ongoing discussions in Folketinget (parliament) about expanding coverage, especially given the cardiovascular benefit data from SELECT trial. The Danish Sundhedsstyrelsen (health authority) is expected to issue new guidelines in mid-2026. One advantage Denmark DOES have: proximity to Novo Nordisk means supply is generally more reliable here. When there are global shortages, Denmark tends to be last affected.

Interesting cross-border note — I live in Malmö, Sweden but work in Copenhagen. I technically have access to both the Swedish and Danish healthcare systems. My Swedish endocrinologist prescribed Wegovy through the Swedish system (covered by förmånen), which I couldn't easily get in Denmark. The Øresund region creates some unique healthcare arbitrage opportunities. Also worth mentioning for anyone in Sweden — online vårdgivare like Kry and Min Doktor can prescribe Ozempic for T2D and refer to specialists for obesity. The digital health infrastructure in Sweden is very advanced.

Since we're doing Nordics — Finland quick update: Ozempic available, covered by Kela (social insurance) for T2D with a B-lausunto (medical statement). For obesity, not covered. Wegovy available privately at around €280/month. The Finnish system is more restrictive than Norway and Sweden for obesity medication coverage. I actually travel to Tallinn, Estonia to buy Ozempic at a lower price — about €85 per pen at Südameapteek pharmacies there.

the Estonia tip is clever. So for the full Nordic picture, Norway > Sweden > Denmark > Finland for obesity GLP-1 coverage. Fascinating how much variation there is among countries with supposedly similar healthcare philosophies.

The variation really comes down to how each country's HTA body evaluates cost-effectiveness. Norway's SLV used a broader societal perspective (including productivity gains and reduced cardiovascular events) which favored coverage. Sweden's TLV initially used a narrower healthcare perspective but revised their analysis. Denmark's Medicinrådet has been the most conservative. For anyone moving between Nordic countries — your medication history transfers through the Nordic e-health cooperation, so a new doctor in any Nordic country can see what you've been prescribed. Makes continuity of care much easier than moving between, say, European and non-European countries.